ReviewAmerican journal of cancer research2025
Multifunctional nanoplatforms based on RNA interference for glioma treatment.
Review in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is the most common malignant tumor in the central nervous system. Currently, common clinical treatments for glioma include surgery, radiation therapy, chemotherapy and immunotherapy, among which the combination of chemotherapy and immunotherapy has attracted wide attention. However, the ability of chemotherapeutic agents and immune checkpoint blockers to reach gliomas is limited due to the existence of blood brain/tumor barrier (BBB/BTB). RNA interference (RNAi) technology enables specific silencing of target genes associated with cancer therapy, so it has been used as an emerging potential cancer treatment strategy. However, Small interference RNA (siRNA) is easily degraded by serum endonuclease, which can be quickly filtered and cleared by the glomerulus. Therefore, design and construction of safe and effective delivery systems is conducive to improving the stability of siRNA and the efficiency of gene silencing. This review focuses on the research progress of nano delivery system based on RNA interference for glioma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.